Bayer

News

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.

News

Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.

News

Things will get tougher before they get better at Bayer, according to CEO Bill Anderson, as the group reports its 2024 financial results.

News

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.

News

Bayer is close to filing a new MRI contrast agent that can reduce levels of gadolinium, which can have health and environmental consequences.

News

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.